Recorded Presentation from the NCCN Pharmacy Updates: Novel Treatments for Neuroendocrine Tumors
While there is a brand new treatment option for neuroendocrine tumors, it requires a wide array of practical guidance to be given safely and effectively.  Practitioners need to be well versed in patient eligibility, patient preparation for treatment, dosing, administration, and management of side effects.
Category
  • Neuroendocrine Tumors
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Gastric Cancer
Clinicians must consider disease stage, histology, biomarker expression and patient performance status to make decisions regarding optimal care. In addition, clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies become available.
Category
  • Gastric/Esophageal Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Establishing a Place in Therapy for Biosimilars in Oncology
Clinical oncology pharmacists have the opportunity to provide education on biosimilars and be a part of the multi-disciplinary decision-making process for incorporating biosimilars into practice sites. In addition, pharmacists will need training on reporting post-marketing surveillance data regarding immunogenicity, product variability and drift of biosimilars as use becomes widespread.
Category
  • Biosimilars
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Central Nervous System Cancers
Histopathologic and molecular characterization of high-grade gliomas should now be standard practice, as specific markers used to define molecular subgroups among some anaplastic gliomas have been shown to have prognostic value. However, there are currently no targeted agents that have shown efficacy in the treatment of glioblastoma. The differential benefit from concurrent versus adjuvant temozolomide in patients with anaplastic gliomas continues to be unclear.
Category
  • Melanoma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date December 18, 2020
New NCCN Guidelines for Pediatric Cancers: Advancements in the Management of Pediatric Acute Lymphoblastic Leukemia
The NCCN Guidelines for pediatric ALL will help inform clinicians about treatment approaches and will shed light on new prognostic markers that could be targeted in pediatric ALL to enhance therapeutic efficacy and minimize treatment-related toxicities.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date January 22, 2021
New NCCN Guidelines for Pediatric Cancers: Management of Pediatric Aggressive Mature B-Cell Lymphoma
Clinician who treat pediatric BL and DLBCL need to be informed about the recommendations in the new NCCN Guidelines for Pediatric Aggressive Mature B-Cell Lymphomas so that they can appropriately stratify patients into risk groups, plan initial therapy, and manage common supportive care issues. They also need information on recommended surveillance protocols and treatment of relapsed/refractory disease.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date February 3, 2021
NCCN Guidelines® Insights - T-Cell Lymphomas, Version 1.2021
Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis.
Category
  • T-Cell Lymphomas
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Lymphoma 101: The Plot Thickens
Educating hematologists and oncologists about these recent advances would help them to use the response criteria and interpret complex clinical trial data more accurately in an era increasingly focused on targeted treatments with prolonged duration of therapy.
Category
  • Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Navigating the Jargon of Molecular Testing
Molecular testing is increasingly being utilized in oncology practice. Practitioners need to know the types of genetic alterations that can be detected, the technologies that can be used to detect these alterations, and the limitations of those techniques in order to ensure that their patients can be appropriately diagnosed, monitored, and matched with targeted therapies or recommended for clinical trials. 
Category
  • Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Controversies in the Management of Early-Stage Hodgkin Lymphoma
Patients with early-stage Hodgkin lymphoma (HL) often experience high cure rates with current therapeutic measures which include chemotherapy alone or chemotherapy and radiotherapy; however, late effects due to treatment-related toxicity is of significant concern. Emerging studies are shedding light on these controversies and clinicians are challenged to remain abreast of these developments to optimize treatment of patients with early-stage HL. 
Category
  • Hodgkin Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages